-
August 2025 Background To create and contribute to the creation of knowledge by undertaking advanced analysis and validation experiments within the MRC BioFlare research programme: Although outcomes in RA
-
recently funded 5-year programme of antifungal drug discovery at the MRC Centre for Medical Mycology. This exciting new programme connects MRC CMM researchers with drug discovery experts and scientists from
-
Demonstrate proficiency in R/BioConductor and High Level (e.g. python) programming languages, Databases (SQL), development and maintaining code repositories (version control) Ability to assess resource
-
programming skills in languages such as Python, MATLAB or R. Familiarity with UNIX/LINUX. High level analytical capability. Ability to communicate complex information clearly. Ability to assess resource
-
to formulate and lead a research programme that will deliver innovative, world-class science in molecular host-microbes interactions or a related field and good knowledge of JIC/NRP research fields, underpinning
-
Research Fellow (Fusion Shielding Materials) - School of Metallurgy and Materials - 105638 - Grade 7
requirements and use resources effectively Understanding of and ability to contribute to broader management/administration processes Contribute to the planning and organising of the research programme and/or
-
programme and/or specific research project Co-ordinate own work with others to avoid conflict or duplication of effort Knowledge of the protected characteristics of the Equality Act 2010, and how to actively
-
organising of the research programme and/or specific research project Co-ordinate own work with others to avoid conflict or duplication of effort Knowledge of the protected characteristics of the Equality Act
-
the project and the Programme team Contribute to writing bids for research funding Contribute to Departmental/School research-related activities and research-related administration Contribute to enterprise
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic